Apollo Hospitals Enterprise Limited has secured a significant regulatory milestone with the National Company Law Tribunal (NCLT) Chennai approving its application for a composite scheme of arrangement. The tribunal's order dated March 26, 2026 paves the way for the healthcare giant to proceed with its strategic restructuring involving three subsidiary companies - Apollo HealthCo, Keimed, and Apollo HealthTech.

NCLT Approval and Meeting Directives

The NCLT Division Bench comprising Hon'ble Member (Judicial) Jyoti Kumar Tripathi and Hon'ble Member (Technical) Ravichandran Ramasamy allowed the application CA (CAA) / 8 / (CHE) / 2026. The tribunal has issued comprehensive directions for convening meetings of various stakeholder groups to consider the proposed scheme.

Companies Involved in the Scheme

The composite arrangement involves four entities with distinct business focuses and capital structures:

Apollo Hospitals Enterprise Limited serves as the demerged company with a paid-up share capital of Rs. 71,89,23,285 comprising 14,37,84,657 equity shares of Rs. 5.00 each. The company operates as a leading healthcare service provider engaged in hospital operations, medical equipment manufacturing, and healthcare education.

Apollo Healthco Limited functions as Transferor Company 1 with a substantial paid-up capital of Rs. 28,86,19,94,770. This includes 41,11,99,477 equity shares and preference shares totaling Rs. 24,75,00,00,000. The company focuses on technology-led healthcare services and online health management platforms.

Keimed Private Limited operates as Transferor Company 2 with Rs. 6,87,29,370 in paid-up capital through 68,72,937 equity shares. The entity specializes in pharmaceutical distribution, e-commerce supply chain management, and medical equipment trading.

Apollo Healthtech Limited represents the resultant company with a modest paid-up capital of Rs. 9,00,000 comprising 4,50,000 equity shares of Rs. 2.00 each. This newly incorporated entity will house the consolidated digital health and pharmacy distribution operations.

Strategic Rationale and Business Benefits

The scheme aims to carve out Apollo Hospitals' identified business undertaking related to digital health and pharmacy distribution into a separate focused entity. Key strategic objectives include:

Meeting Procedures and Compliance

The NCLT has appointed Sri K S Ravichandran as Chairperson for the meetings with a fee of Rs. 2,50,000 plus expenses. Vedavel, Advocate, will serve as Scrutinizer with compensation of Rs. 1,20,000 plus expenses.

Several meetings have been dispensed with due to 100% consent obtained through affidavits, including equity shareholders of Apollo Healthco (14 shareholders), Keimed Private Limited (48 shareholders with 99.94% consent), and Apollo Healthtech Limited (8 shareholders).

Next Steps and Regulatory Requirements

The scheme remains subject to approval from shareholders and creditors in the scheduled meetings, along with necessary statutory and regulatory approvals. The final sanction from the NCLT will be required following successful completion of the stakeholder approval process. The company must comply with all directions under the Companies Act, 2013 and applicable rules for compromises, arrangements, and amalgamations.

Apollo Hospitals Enterprise Limited has announced its board's approval for establishing a multi-speciality hospital at Dwarka, New Delhi, marking a significant expansion in the National Capital Region. The decision was taken during the Board of Directors meeting held on April 2, 2026, which commenced at 4:00 p.m. and concluded at 5:45 p.m.

Project Overview

The multi-speciality hospital project will be developed on a substantial land parcel measuring 9.33 acres, which is being leased from the Delhi Development Authority (DDA). The project represents Apollo Hospitals' strategic expansion into one of Delhi's prominent residential and commercial hubs.

Lease Agreement Terms

The land lease arrangement with the Delhi Development Authority encompasses several key provisions that will govern the project's development and operations. The agreement establishes a long-term commitment for healthcare infrastructure development in the region.

Implementation Strategy

The hospital project will be implemented through a phased approach, allowing for systematic development and gradual scaling of healthcare services. Apollo Hospitals plans to incorporate a Special Purpose Vehicle (SPV) specifically for the execution and implementation of this project, ensuring focused management and operational efficiency.

The development will focus on creating a super specialty hospital with allied healthcare services, positioning it as a comprehensive healthcare destination in the Dwarka area. The formal License Agreement is expected to be executed within one year of the board approval.

Regulatory Compliance

The announcement was made in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The project involves a domestic entity arrangement with no related party transactions or promoter group interests in the land-awarding authority.

This expansion initiative reinforces Apollo Hospitals' commitment to extending quality healthcare infrastructure across key metropolitan areas, with the Dwarka facility expected to serve the growing healthcare needs of Delhi's western corridor.